BIOLASE Reports 2019 Fourth Quarter; Net Revenue Increased 18% Sequentially

Date : 03/26/2020 @ 8:05PM
Source : PR Newswire (US)
Stock : Biolase Inc (BIOL)
Quote : 0.235  -0.006 (-2.49%) @ 5:00AM
After Hours
Last Trade
Last $ 0.25 ▲ 0.01 (5.96%)

BIOLASE Reports 2019 Fourth Quarter; Net Revenue Increased 18% Sequentially

Biolase (NASDAQ:BIOL)
Historical Stock Chart

1 Month : From Mar 2020 to Apr 2020

Click Here for more Biolase Charts.

IRVINE, Calif., March 26, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $10.2 million and $37.8 million for the fourth quarter and year ended December 31, 2019, respectively.

BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

Sequential Fourth Quarter Results Demonstrate Sequential Operating Momentum

  • Net revenue increased 18% sequentially
  • U.S. laser revenue increased 44% sequentially
  • International laser revenue increased 2% sequentially
  • Worldwide consumables and other revenue increased 1% sequentially
  • GAAP net loss decreased 48% year over year to $3.6 million
  • Adjusted EBITDA loss decreased 39% year over year to $1.6 million
  • Epic Hygiene laser for dental hygienists received FDA clearance in U.S.

"We made significant progress in 2019 as we continued to transition BIOLASE from an R&D-centric company into a commercially-focused business," commented Todd Norbe, President and Chief Executive Officer.  "I believe the sequential improvement in the fourth quarter demonstrates the early success of our go-to-market strategy, under which we continue to rationalize our cost structure and rebuild our salesforce into a more disciplined customer-centric organization that is beginning to create positive change. I believe we have the right leadership team in place to achieve our growth and profitability objectives going forward.

"In December 2019, we received FDA clearance for our Epic Hygiene laser for dental hygienists, representing the achievement of another significant regulatory milestone, and just this week we received FDA clearance for LBR (laser bacterial reduction). This new laser system provides dental professionals a total solution to effectively manage non-surgical periodontitis. Our goal is to expand the reach of this great technology through increased awareness and improved sales and marketing execution. 

"Lastly, I want to acknowledge the impact of the coronavirus pandemic and express our heartfelt concern to those who have been impacted. The safety of our employees, customers, partners and patients is paramount and we are taking every precaution to ensure their well-being during this difficult period as we face COVID-19. While it's our hope that this situation is controlled as soon as possible, the matter remains very fluid and it's difficult to predict when commercial activities, and more specifically, the dental market will return to normal levels. Given the recent dental office closures worldwide, we expect our first quarter 2020 sales to be down significantly year over year. Prior to the coronavirus pandemic we felt strongly that having filled almost all of our open U.S. sales territories would lead to year over year revenue improvement for the last three quarters of 2020, however, whether we can achieve this now depends on how quickly our U.S. and international business returns to some level of normalcy." 

2019 Fourth Quarter Financial Results

Net revenue for the fourth quarter of 2019 was $10.2 million, up 18% from the third quarter of 2019, and down 22% year over year compared to net revenue of $13.0 million for the fourth quarter of 2018. U.S. laser revenue was $3.3 million for the fourth quarter of 2019, up 43% from the third quarter of 2019, and down 41% compared to U.S. laser revenue of $5.6 million for the fourth quarter of 2018. U.S. consumables and other revenue for the fourth quarter of 2019, which consists of revenue from consumable products such as disposable tips, was down 3% compared to the third quarter of 2019 and down 29% year over year compared to the fourth quarter of 2018. International laser revenue increased to $3.5 million for the fourth quarter of 2019, up 2% both compared to the third quarter of 2019 $3.4 million for the fourth quarter of 2018.

Gross margin for the fourth quarter of 2019 was 43%, the same as for the fourth quarter of 2018, despite lower revenue. Total operating expenses were $7.5 million for the fourth quarter of 2019 compared to $12.1 million for the fourth quarter of 2018, a decrease of $4.7 million or 39% year over year. Operating loss for the fourth quarter of 2019 was $3.0 million, compared to an operating loss of $6.5 million for the fourth quarter of 2018, a decrease of $3.5 million year over year. The net loss for the fourth quarter of 2019 was $3.6 million, or $0.13 per share, compared to a net loss of $6.9 million, or $0.33 per share, for the fourth quarter of 2018.

For the fourth quarter of 2019, the Company had a $1.6 million, or $0.05 per share, Adjusted EBITDA loss compared with an Adjusted EBITDA loss of $2.7 million, or $0.13 per share, for the fourth quarter of 2018. A reconciliation of GAAP net loss to Adjusted EBITDA on an aggregate and a per share basis is at the end of this news release.

Cash, cash equivalents, and restricted cash totaled $6.1 million as of December 31, 2019.

Full Year 2019 Financial Results

Net revenue for the year ended December 31, 2019 was $37.8 million, a decrease of 18% compared to net revenue of $46.2 million for the year ended December 31, 2018. U.S. laser revenue was $11.1 million for the year ended December 31, 2019, a decrease of 28% compared to U.S. laser revenue of $15.5 million for the year ended December 31, 2018. U.S. consumables and other revenue for the year ended December 31, 2019, which consists of revenue from consumable products such as disposable tips, decreased 11% year over year. International laser revenue decreased to $11.7 million for the year ended December 31, 2019 compared to $14.2 million for the year ended December 31, 2018.

Gross margin for the year ended December 31, 2019 was 38% compared to 37% for the year ended December 31, 2018. Total operating expenses were $29.9 million for the year ended December 31, 2019 compared to $37.8 million for the year ended December 31, 2018, a decrease of $7.9 million year over year. Operating loss for the year ended December 31, 2019 was $15.6 million, compared to an operating loss of $20.9 million for the year ended December 31, 2018, a decrease of $5.3 million year over year. The net loss for the year ended December 31, 2019 was $17.9 million, or $0.77 per share compared to a net loss of $21.5 million, or $1.05 per share for the year ended December 31, 2018.

Adjusted EBITDA for the year ended December 31, 2019 was a loss of $10.4 million, or $0.44 per share compared with an Adjusted EBITDA loss of $14.5 million, or $0.71 per share for the year ended December 31, 2018.

Conference Call Information

BIOLASE, Inc. will host a conference call March 26, 2019 at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and full year ended December 31, 2019 and to discuss the expected impact of the COVID-19 pandemic on BIOLASE's business. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 800-353-6461. For international participants outside the U.S./Canada, the dial-in number is 334-323-0501. For all callers, refer to the Conference ID 7830999. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see "Investor Events".

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately patented 208 and 56 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold over 41,000 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the go-to-market sales strategy and anticipated sales during the first quarter of 2020. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," "should," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith,  adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

Tables Follow

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)























Three Months Ended



Twelve Months Ended



December 31,



December 31,



2019



2018



2019



2018

Net revenue


$


10,182



$


13,045



$


37,799



$


46,155

Cost of revenue




5,765





7,432





23,511





29,260

Gross profit




4,417





5,613





14,288





16,895

Operating expenses:




















Sales and marketing




3,731





5,084





14,396





18,121

General and administrative




2,634





3,080





10,748





11,771

Engineering and development




1,100





1,276





4,765





5,203

Disposal of internally developed software








1,185









1,185

Loss on patent litigation settlement








1,500









1,500

Total operating expenses




7,465





12,125





29,909





37,780

Loss from operations




(3,048)





(6,512)





(15,621)





(20,885)

Loss on foreign currency transactions




33





5





121





58

Interest expense, net




598





430





2,157





510

Non-operating loss




631





435





2,278





568

Loss before income tax provision




(3,679)





(6,947)





(17,899)





(21,453)

Income tax provision (benefit)




(111)





(28)





(44)





63

Net loss


$


(3,568)



$


(6,919)



$


(17,855)



$


(21,516)





















Deemed dividend on convertible preferred stock:


$




$




$




$


Net loss per share attributable to common stockholders:


$


(3,568)



$


(6,919)



$


(17,855)



$


(21,516)

Basic


$


(0.13)



$


(0.33)



$


(0.77)



$


(1.05)

Diluted


$


(0.13)



$


(0.33)



$


(0.77)



$


(1.05)

Shares used in the calculation of net loss per share:




















Basic




28,118





20,732





23,202





20,588

Diluted




28,118





20,732





23,202





20,588

 

BIOLASE, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)













December 31,



December 31,



2019



2018



(unaudited)



(unaudited)

ASSETS










Current assets:










Cash and cash equivalents


$


5,789



$


8,044

Restricted cash




312





312

Accounts receivable, less allowance of $2,531 and $850 in 2019 and 2018, respectively




8,760





11,112

Inventory




10,995





12,248

Prepaid expenses and other current assets




1,163





1,591

Total current assets




27,019





33,307

Property, plant and equipment, net




1,193





1,975

Goodwill




2,926





2,926

Right of use asset




276





Other assets




433





308

Total assets


$


31,847



$


38,516











LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY










Current liabilities:










Accounts payable


$


5,332



$


5,953

Accrued liabilities




4,744





7,538

Deferred revenue




2,237





2,476

Term loan




13,466





Total current liabilities




25,779





15,967

Deferred income taxes, net




78





77

Deferred revenue, noncurrent




358





Warranty accrual, noncurrent




245





447

Other liabilities




1,045





100

Term loan








10,836

Total liabilities




27,505





27,427

Redeemable preferred stock:










Preferred stock, par value $0.001 per share


$


3,965



$


Total redeemable preferred stock




3,965





Stockholders' equity:










Common stock, par value $0.001 per share




31





21

Additional paid-in capital




235,594





228,430

Accumulated other comprehensive loss




(701)





(670)

Accumulated deficit




(234,547)





(216,692)

Total stockholders' equity




377





11,089

Total liabilities, redeemable preferred stock and stockholders' equity


$


31,847



$


38,516

 

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)











Twelve Months Ended



December 31,



2019



2018

Cash Flows from Operating Activities:








Net loss


$

(17,855)



$

(21,516)

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:








Depreciation and amortization



982




945

Loss on disposal of assets






1,228

Provision for bad debts



1,695




469

Provision for inventory excess and obsolescence



413




166

Amortization of debt discounts



140




202

Amortization of debt issuance costs



188




126

Stock-based compensation



2,742




2,768

Warrants issued to consultants



48




Loss on patent litigation settlement






1,500

Deferred income taxes



7




(27)

Earned interest income, net



2




1

Changes in operating assets and liabilities:








Accounts receivable



655




(1,458)

Inventory



840




(127)

Prepaid expenses and other current assets



439




(25)

Accounts payable and accrued liabilities



(3,156)




1,762

Deferred revenue



114




(161)

Net cash and cash equivalents used in operating activities



(12,746)




(14,147)

Cash Flows from Investing Activities:








Purchases of property, plant, and equipment



(207)




(558)

Proceeds from disposal of property, plant, and equipment






36

Net cash and cash equivalents used in investing activities



(207)




(522)

Cash Flows from Financing Activities:








Principal payments under capital lease obligation






(46)

Borrowings under lines of credit






3,696

Payments under line of credit






(3,696)

Borrowings under term loan



2,500




12,500

Payments of debt issuance costs



(133)




(1,058)

Proceeds from equity offering costs, net of expenses



9,171




Payments of equity offering costs



(821)




(164)

Proceeds from exercise of stock options



4




3

Net cash and cash equivalents provided by financing activities



10,721




11,235

Effect of exchange rate changes



(23)




(106)

Decrease in cash, cash equivalents and restricted cash



(2,255)




(3,540)

Cash, cash equivalents and restricted cash, beginning of period



8,356




11,896

Cash, cash equivalents and restricted cash, end of period


$

6,101



$

8,356

Supplemental cash flow disclosure - cash paid








Cash paid for interest


$

1,784



$

23

Cash paid for income taxes


$

35



$

44

Cash paid for operating leases


$

797



$

Supplemental cash flow disclosure - non cash








Non-cash accrual for capital expenditures


$

18



$

31

Non-cash accrual for equity offering costs


$

129



$

Non-cash right-of-use assets obtained in exchange for lease obligation


$

276



$

Loss on patent litigation settlement


$



$

1,500

Settlement of liability awards


$

201



$

Warrants issued in connection with debt instruments


$

161



$

847

Non-GAAP Disclosure

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents. In 2019, the Company revised its non-GAAP financial measures to include the change in allowance for doubtful accounts in an effort to better align its Adjusted EBITDA with our loan covenants and how management evaluates business performance. Prior year non-GAAP disclosures have been revised to conform to the current definition of Adjusted EBITDA.

Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation and allowance for doubtful accounts. Management uses adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

BIOLASE, INC.

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(Unaudited)

(In thousands, except per share data)









Three Months Ended



Twelve Months Ended



December 31,



December 31,



2019



2018



2019



2018

GAAP net loss attributable to common stockholders


$


(3,568)



$


(6,919)



$


(17,855)



$


(21,516)

Deemed dividend on convertible preferred stock
















GAAP net loss


$


(3,568)



$


(6,919)



$


(17,855)



$


(21,516)

Adjustments:




















Interest expense, net




598





430





2,157





510

Income tax provision (benefit)




(111)





(28)





(44)





63

Depreciation and amortization




215





233





969





945

Change in allowance for doubtful accounts




452









1,681





Disposal of internally developed software








1,185









1,185

Loss on patent litigation








1,500









1,500

Stock-based compensation




769





906





2,742





2,768

Adjusted EBITDA


$


(1,645)



$


(2,693)



$


(10,350)



$


(14,545)





















GAAP net loss attributable to common stockholders per share, basic and diluted


$


(0.13)



$


(0.33)



$


(0.77)



$


(1.05)

Deemed dividend on convertible preferred stock
















GAAP net loss per share, basic and diluted


$


(0.13)



$


(0.33)



$


(0.77)



$


(1.05)

Adjustments:




















Interest expense, net




0.02





0.02





0.09





0.02

Income tax provision (benefit)
















Depreciation and amortization




0.01





0.01





0.04





0.05

Change in allowance for doubtful accounts




0.02









0.07





Disposal of internally developed software








0.06









0.06

Loss on patent litigation








0.07









0.07

Stock-based compensation




0.03





0.04





0.12





0.13

Adjusted EBITDA, basic and diluted


$


(0.05)



$


(0.13)



$


(0.44)



$


(0.71)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-reports-2019-fourth-quarter-net-revenue-increased-18-sequentially-301030616.html

SOURCE BIOLASE, Inc.

Copyright 2020 PR Newswire

Latest BIOL Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.